GERMAIN MARK 4

What Happened

• Mark Germain, a director of Scinai Immunotherapeutics Ltd. (SCNI), was granted 120,000,000 Ordinary Shares as a restricted share award on June 16, 2026. The grant is reported at a $0.00 acquisition price (i.e., award/grant rather than a purchase or sale). The shares are represented by restricted share units (RSUs) that vest over time.

Key Details

• Transaction date: 2026-06-16; Form 4 filed: 2026-06-18 (filed timely).
• Reported acquisition: 120,000,000 Ordinary Shares at $0.00 (grant/award code A).
• Vesting: These 120,000,000 Ordinary Shares are represented by RSUs that vest in three equal annual installments, subject to continued service (footnote F2).
• ADS equivalence: The filing notes each American Depositary Share (ADS) currently represents 4,000 Ordinary Shares, so the grant is equivalent to 30,000 ADS at the stated ratio (footnote F1).
• Shares owned after transaction: not specified in the provided excerpt of the filing.

Context

• This was an award (compensation) grant, not an open-market purchase or sale. RSUs typically cannot be sold or voted until they vest and convert to actual shares/ADS. A $0.00 acquisition price reflects the nature of the grant reporting, not the market value of the shares.